Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive source : Alzamend.com save search
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.729 0.47% 9.5K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al001 alzheimer treatment dementia trial phase 1 positive topline alzheimer’s alzheimer's
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.729 0.47% 9.5K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al002 alzheimer fda system disease cel positive pons vaccine alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.